Healthcare Business

145922793

UnitedHealth Group Revenues Stung by Obamacare

UnitedHealth Group Inc. (NYSE: UNH) reported first-quarter results before markets opened Thursday. The health insurance and benefits management firm posted diluted earnings per share (EPS) of $1.10 on revenues of ...
Read Full Story »
health care

Medical Device Maker’s IPO a Modest Success

Some initial public offerings (IPOs) are considered a huge success if the stock appreciates more than about 20% on its IPO date. To some, though, that's an unsuccessful launch from ...
Read Full Story »
95992888

Why Lpath Could Rise 300%

Canaccord Genuity is one of the few firms that are willing to cover small-cap biotech and emerging pharma stocks. Sometimes the price target upside is off the charts as well. ...
Read Full Story »
Johnson & Johnson Logo

Johnson & Johnson Earnings Point to New 52-Week High

Johnson & Johnson (NYSE: JNJ) reported first-quarter results before markets opened Tuesday. The health care giant reported quarterly adjusted diluted earnings per share (EPS) of $1.54 on revenue of $18.1 ...
Read Full Story »
buy sell

Gilead Risks Beyond Just Merck: Serious Chart Violation Watch

Gilead Sciences Inc. (NASDAQ: GILD) may have been largely responsible for the drop in biotech stocks after politicians went after its drug costs, but an excessive multiyear performance above and ...
Read Full Story »
Biotechnology word cloud

Who Bucked the Short Interest Trend in Biotech Stocks?

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. Many biotech stocks pulled back in late March, and short sellers moved in on many ...
Read Full Story »
biotech

Why Questcor Buyout Will Not Deter Short Sellers

The $5.6 billion acquisition of Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) by specialty drugmaker Mallinckrodt PLC (NYSE: MNK) started the week off with a big bang. Shares of Questcor originally leaped ...
Read Full Story »
Food and Drug Administration logo

FDA Keeps Driving Up Future Cost of Inhalable Insulin

MannKind Corp. (NASDAQ: MNKD) is suffering another setback from the U.S. Food & Drug Administration. While the FDA has been far from a friend to MannKind over the past few ...
Read Full Story »
research

Credit Suisse Says Grit Your Teeth and Buy Biotech

For the second time since late February, a huge run on the momentum, and specifically biotech, names hit the market last week. Again, the biotech benchmark took a huge 4% ...
Read Full Story »
DNA

Pancreatic Cancer Trial Enrollment Halt Damages Halozyme

Halozyme Therapeutics Inc. (NASDAQ: HALO) will need some therapeutics of its own, as are its shareholders. Its shares got pounded Friday morning on news of a temporary halt of its ...
Read Full Story »
Biotechnology word cloud

Stifel Says Strong Earnings Will Reignite Biotech Rally

When the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering and intense selling knocked a quick 17% off the index ...
Read Full Story »
biotech

Amgen Faces Cool Reception Over GSK Pact Termination

Amgen Inc. (NASDAQ: AMGN) submitted an SEC Filing showing that, as of April 1, its Amgen Manufacturing Ltd. subsidiary and GlaxoSmithKline PLC (NYSE: GSK), via Glaxo Group Ltd., have terminated ...
Read Full Story »
Pills

Jefferies Biotech Stocks to Buy With Breakthrough Drug Innovations

New drug innovations are affecting the way that physicians treat such debilitating and deadly diseases as cancer. In a new research report, Jefferies presents the top drug innovations that investors ...
Read Full Story »
Stock Split Image

Biotech Giants Now Priced Like Old World Drug Stocks

Most investors buying Big Pharma stocks these days are buying them for dividends and somewhat of a defensive position against stock market volatility. Investors who are buying biotechs generally are ...
Read Full Story »
DNA

Large Cap Biotechs Trading With Only Big Pharma P/E Ratios

The iShares Nasdaq Biotechnology (NASDAQ: IBB) exchange traded fund (ETF) has pulled back almost 17% since the February 25 peak, in a sell-off likened to the August 2011 debacle. Trading ...
Read Full Story »